Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results

02.01.26 14:00 Uhr

Werte in diesem Artikel

MARLBOROUGH, Mass., Jan. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, in San Francisco. Mike Mahoney, chairman and chief executive officer, Jon Monson, executive vice president and chief financial officer, and Ken Stein, M.D., senior vice president and global chief medical officer, will participate in a 40-minute question-and-answer session with the host analyst. The session will begin at approximately 9:00 a.m. PT / 12:00 p.m. ET.

Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation)

Additionally, the company will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2025, on Wednesday, February 4, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Jon Monson. The company will issue a news release announcing financial results for the fourth quarter and full year 2025 on February 4 prior to the conference call.

A live webcast and replay for each event will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.

About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn

CONTACTS:
Emily Anderson
Media Relations
+1 (617) 515-2000
Emily.Anderson2@bsci.com

Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-participation-in-the-jp-morgan-healthcare-conference-and-conference-call-discussing-fourth-quarter-and-full-year-2025-results-302648097.html

SOURCE Boston Scientific Corporation

In eigener Sache

Übrigens: Boston Scientific und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Boston Scientific

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Boston Scientific

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Boston Scientific Corp.

Wer­bung

Analysen zu Boston Scientific Corp.

DatumRatingAnalyst
03.09.2019Boston Scientific OverweightBarclays Capital
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
03.09.2019Boston Scientific OverweightBarclays Capital
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
28.04.2016Boston Scientific NeutralWedbush Morgan Securities Inc.
04.05.2015Boston Scientific HoldDeutsche Bank AG
05.02.2015Boston Scientific HoldDeutsche Bank AG
30.09.2014Boston Scientific HoldNeedham & Company, LLC
07.01.2013Boston Scientific haltenDeutsche Bank Securities
DatumRatingAnalyst
13.04.2010Boston Scientific "sell"Goldman Sachs Group Inc.
17.03.2010Boston Scientific DowngradeGoldman Sachs Group Inc.
10.10.2008Boston Scientific below averageCaris & Company, Inc.
02.10.2008Boston Scientific DowngradeMerrill Lynch & Co., Inc.
13.12.2007Boston Scientific underperformFriedman, Billings Ramsey & Co

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Boston Scientific Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen